Our results demonstrate for the first time that the combination of ruxolitinib, a JAK1/2i with resminostat, a HDACi demonstrates efficacy in an in vitro model of CTCL, highlighting its significance as a promising novel therapeutic modality for CTCL patients that fail to benefit from monotherapy. This evidence concerns the gene JAK1 and primary cutaneous T-cell non-Hodgkin lymphoma.